The treatment, CYT387, appears to demonstrate an ability to render and maintain myelofibrosis patients transfusion independent for clinically-relevant periods, while also improving other symptoms, according to a phase I and phase II study.
Another key feature is a comparison recommendation engine for health plans that people can use during their open enrollment periods or when choosing an independent health plan.